FindTrial
Sign In

The Effects of Resveratrol on Postmenopausal Women with Coronary Artery Disease

The Effects of Resveratrol on Sirtuins-1 and -3, Soluble Receptors for Advanced Elycation End Products, and Gene Expression of Inhibitors of Apoptosis Proteins in Postmenopausal Women with Coronary Artery Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7d7cycj
Enrollment
Unknown
Registered
2025-09-05
Start date
2023-03-06
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Heart Disease

Interventions

A randomized, double-blind, parallel, placebo-controlled clinical trial will be conducted on postmenopausal women with coronary artery disease who receive 90 days of daily supplementation with 1g of r
D02.455.426.559.389.657.715.500

Sponsors

Instituto do Coração da Faculdade de Medicina da Universidade de São Paulo
Lead Sponsor
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Collaborator

Eligibility

Sex/Gender
Female
Age
55 Years to No maximum

Inclusion criteria

Inclusion criteria: postmenopausal women (more than one year of amenorrhea) aged equal or higher than 55 years; stable chronic coronary artery disease documented by coronary angiography with at least one coronary lesion with higher than 50% reduction in vascular lumen; and BMI higher than 21.9 kg/m2

Exclusion criteria

Exclusion criteria: dyslipidemia with plasma triglycerides level equal or higher than 500 mg/dL and total cholesterol equal or higher than 300 mg/dL; acute coronary syndrome (6 months or less); congenital heart disease; recent surgery (6 months or less); chronic renal failure, liver failure, clinically significant genetic, hematologic, rheumatic, respiratory, or metabolic diseases

Design outcomes

Primary

MeasureTime frame
An increase in absolute levels of circulating sirtuin-1, quantified by ELISA kit using plasma, is expected—

Secondary

MeasureTime frame
No secondary outcomes are expected—

Countries

Brazil

Contacts

Public ContactAntonio Mansur

Instituto do Coração da Faculdade de Medicina da Universidade de São Paulo

apmansur@usp.br+55(11)26615448

Outcome results

None listed

Source: REBEC (via WHO ICTRP)